MariMed Announces the Filing of its final Non-Offering Prospectus
MariMed, Inc. (OTCQX: MRMD) announced the receipt of its final long-form prospectus from the Ontario Securities Commission, positioning the company for a dual listing on the Canadian Securities Exchange (CSE). The anticipated listing under the symbol MRMD is projected to occur in July 2022, pending the completion of customary conditions. CFO Susan Villare stated that this move aims to enhance liquidity and trading volume, making it easier for investors to trade MariMed shares.
- Dual listing on CSE expected to improve liquidity and trading volume.
- Conditional approval from the CSE confirms strategic business advancement.
- None.
Sets Stage For Dual Listing on the Canadian Securities Exchange
NORWOOD, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- MariMed, Inc. (“MariMed” or the “Company”) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced that it has obtained a receipt for its final non-offering, long form prospectus dated June 29, 2022 from the Ontario Securities Commission.
Concurrent with its prospectus filing, the Company also received conditional approval from the Canadian Securities Exchange (the “CSE”) to list the Company’s common shares on the CSE under the symbol "MRMD". Listing of the common shares is subject to the satisfaction of certain customary conditions, including the receipt by the CSE of all final documentation. The Company anticipates the dual listing on the CSE to be effective in July of 2022.
“Completing the prospectus filing process is the last significant milestone necessary to fulfill the Company’s goal of attaining a dual listing on the CSE,” said Susan Villare, Chief Financial Officer of MariMed. “We believe this listing will improve liquidity enabling increased trading volume and allow for more accessible trading for some investors that currently cannot invest in MariMed.”
A copy of the final Prospectus is available under the Company’s profile on SEDAR at https://www.sedar.com.
ABOUT MARIMED
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty's Eddies, Nature’s Heritage, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit www.marimedinc.com.
For More Information, Contact:
Investor Relations:
Steve West, Vice President, Investor Relations
Email: ir@marimedinc.com
Media Contact:
Howard Schacter, Chief Communications Officer
Email: h.schacter@marimedinc.com
FAQ
What is MariMed's stock symbol for the Canadian Securities Exchange?
When is MariMed expected to list on the Canadian Securities Exchange?
What regulatory body issued the prospectus for MariMed's dual listing?
How will MariMed's dual listing affect investors?
